Quantcast

Latest Nanobodies Stories

2012-03-29 23:36:46

Creating a radioactive antibody fragment may allow scientists to identify fat and debris deposits in artery walls that are most likely to rupture and cause heart attacks. Of the more than 17 million annual cardiovascular deaths worldwide, most result from ruptured plaque. "The detection of vulnerable coronary plaques is a major clinical challenge because it would allow preventive patient management prior to a heart attack," said Alexis Broisat, Ph.D., the study's lead author and a...

7e36aa130c1fcc214cfd092bf8f986e0
2011-07-14 11:26:43

Nanobodies produced by camels have unique properties, which can be used in future drug development. New research published in the Journal of Controlled Release confirms that nanobodies can help scientists in the fight against cancer. Members of the camelid family have particular heavy-chain antibodies in their blood known as nanobodies, that may serve as therapeutic proteins. One of the most powerful advantages of nanobodies is that they can be easily attached to other proteins and...

c0060ce8098fd38753b5d63dfde98e1e1
2010-01-21 10:20:00

The finding may lead to improved techniques for testing water and food supplies should botulinin neurotoxins be used as a bioterrorism weapon Scientists at the Southwest Foundation for Biomedical Research (SFBR) have for the first time developed a highly sensitive means of detecting the seven types of botulinum neurotoxins (BoNTs) simultaneously. The BoNT-detecting substances are antibodies -- proteins made by the body to fight diseases -- found in llamas. BoNT are about 100 billion times...

2009-10-26 13:15:00

NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications http://www.reportlinker.com/p0155768/Reportlinker-Adds-Immunotherapies-and-Vaccines-for-Nontraditional-Indications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Executive Summary The earliest immunotherapies were vaccines that stimulate the immune system's...

2008-10-06 12:00:43

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. Therapeutic Monoclonal Antibodies Report 2008-2023 http://www.reportlinker.com/p096392/Therapeutic-Monoclonal-Antibodies-Report-2008-2023.html This brand new report investigates the global market for therapeutic monoclonal antibodies. While the pharmaceutical industry as a whole is suffering from single digit growth, thinner pipelines than before and...

2008-10-06 12:00:30

Ablynx, a biopharmaceutical company focused on the discovery and development of nanobodies, has received a grant worth E1.8 million from the Institute for the Promotion of Innovation by Science and Technology in Flanders. The grant, which is over three years, allows Ablynx to further develop technologies related to its Nanobody platform. Furthermore, this grant will enable Ablynx to expand its intellectual property portfolio. Edwin Moses, CEO and chairman of Ablynx, said: "We are...

1f5f20ccf84ea9e4eb75ca859981bbb21
2008-09-12 12:44:49

The head of biotech research GlaxoSmithKline Plc said a new generation of "slimline" antibody medicines may be successors to current blockbusters such as Avastin and Rituxan. Ian Tomlinson headed the next-generation antibody firm Domantis until Glaxo bought it for $405 million in 2006. Now a coming wave of ultra-small antibody products capable of working in ways impossible for conventional treatments is gaining attention. Tomlinson said he thinks the next generation approaches have tremendous...

2008-09-05 09:00:38

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has entered into an agreement with Ablynx, to co-discover and co-develop Nanobodies against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of E10 million. Nanobodies are a new class of therapeutic proteins that contain the unique structural and functional properties of naturally occurring single domain antibodies. The partners will collaborate to research and develop...

2008-09-04 03:00:25

Ablynx and Merck Serono to equally contribute to discover and develop Nanobodies(R) against two targets in oncology and immunology and equally share the resulting profits Ghent, BELGIUM, 4 September 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies(R), a novel class of antibody-derived therapeutic proteins, today announced that it has entered into an agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related